Continuous Glucose Monitors May Help Alleviate Care Burden for Parents of Young Children with T1D
Drug Topics
DECEMBER 1, 2023
A new study found that glucose monitoring devices can help significantly improve the sleep of both parents and children.
Fri.Dec 01, 2023
201 
Addressing Burnout: Employees Are Lonelier Than Ever
Pharmacy Times
DECEMBER 1, 2023
Many workers don’t advertise their level of loneliness, nor do they know the impact of loneliness on their well-being.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
People with congenital heart disease are living longer — but facing new threat of heart failure
STAT
DECEMBER 1, 2023
When Jennifer Case was living in Los Angeles in her early 30s, she was hospitalized 11 times. She had been born with two rare heart abnormalities, Ebstein anomaly and Wolff-Parkinson-White syndrome. Her parents were told that she probably wouldn’t live.
Removing Medicaid Prior Authorizations for Buprenorphine May Not Increase Prescribing
Pharmacy Times
DECEMBER 1, 2023
Non-expansion states had an increase in prescriptions after PA removal at 27.3% and Medicaid expansion states demonstrated a 22% decrease in prescriptions.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Analysts say a Cigna-Humana merger is likely to face major antitrust opposition. But here's how the payers could eke out a win
Fierce Healthcare
DECEMBER 1, 2023
Analysts say a Cigna-Humana merger is likely to face major antitrust opposition.
Gene Associated With Autism Spectrum Disorder May Disrupt Early Brain Development
Pharmacy Times
DECEMBER 1, 2023
Patients with this genetic variant have impaired neuronal excitability, a trait that has been linked to malfunctional synapses.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Phase 2 Trial Data Show That Novel Antibiotic Led to 96% Cure Rate for C diff Infection
Pharmacy Times
DECEMBER 1, 2023
Iberzaplstat was non-inferior to standard of care vancomycin, was safe and tolerable, and will advance into a phase 3 trial.
STAT+: U.S. Supreme Court to review controversial Purdue Pharma bankruptcy settlement
STAT
DECEMBER 1, 2023
After weeks of anticipation, the U.S. Supreme Court on Monday will hear arguments to decide the fate of a controversial bankruptcy deal in which the owners of Purdue Pharma would contribute up to $6 billion in exchange for immunity from further lawsuits. The company was accused of downplaying the risks of OxyContin and improperly persuading physicians to prescribe the addictive painkiller.
Study: Cholesterol in Brain Associated Alzheimer Disease, Brain Damage
Pharmacy Times
DECEMBER 1, 2023
Investigators believe lowering cholesteryl ester levels could help prevent brain damage and behavioral changes, reducing the risk of Alzheimer disease.
STAT+: Pfizer to halt development of its twice-daily oral obesity drug, following disappointing trial
STAT
DECEMBER 1, 2023
Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications. The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Acoustic Stimulation May Significantly Impact Adults Who Have Persistent Symptoms Following Concussion
Pharmacy Times
DECEMBER 1, 2023
Following acoustic stimulation intervention, many patients experienced a reduction in neurobehavioral symptoms.
STAT+: Patients wants test results now, and radiologists need time to explain. Can they meet in the middle?
STAT
DECEMBER 1, 2023
One of the hardest parts about getting an X-ray or a CT scan is the wait. Sometimes it takes days, or even weeks, for medical imaging results to be analyzed by a radiologist, transferred to a primary doctor, and then delivered to the patient — good news or bad. Today, that hand-wringing delay has been nearly eliminated. In 2021, provisions from the 21st Century Cures Act kicked in that require health centers to provide patients with access to their health information on request — i
Potential Host, Viral Mediators of NSV Identified, May Represent Targets to Disrupt HIV Persistence
Pharmacy Times
DECEMBER 1, 2023
Further research of these mechanisms could be significant in developing future strategies to disrupt the viral persistence in individuals living with HIV.
Johnson & Johnson bets heavy on AI-driven drug discovery
STAT
DECEMBER 1, 2023
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we talk about Pfizer’s obesity woes, how J&J is leaning heavily into artificial intelligence, chat about how ADCs are having a heyday, and ponder the zombie microcap.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Study: Income Associated With Cardiologist Care for Those With Heart Failure
Pharmacy Times
DECEMBER 1, 2023
Although involvement of a cardiologist for heart failure has been associated with reduced rates of in-hospital mortality, not all patients see a cardiologist when hospitalized, according to the investigators.
FDA starts review of Padcev/Keytruda for bladder cancer
pharmaphorum
DECEMBER 1, 2023
FDA starts review of Padcev/Keytruda for bladder cancer Phil.
Enhancing Patient-Centric Oncology Care: The Crucial Role of Oncology Pharmacists in Treatment Decision-Making
Pharmacy Times
DECEMBER 1, 2023
Marlo Blazer, PharmD, BCOP, discusses the collaborative nature of the pharmacist's role within the oncology care team.
How to advance more late-stage neuroscience drugs to regulatory approval
pharmaphorum
DECEMBER 1, 2023
How to advance more late-stage neuroscience drugs to regulatory approval Mike.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
AbbVie agrees $10 billion oncology acquisition
European Pharmaceutical Review
DECEMBER 1, 2023
AbbVie has agreed to acquire ImmunoGen and its first-in-class antibody-drug conjugate (ADC) ELAHERE ® (mirvetuximab soravtansine-gynx), for a total of approximately $10.1 billion. The antibody-drug conjugate is the first to be approved for platinum-resistant ovarian cancer (PROC) and show meaningful survival benefit for this form of the disease. As a folate receptor alpha (FRα) with a maytansinoid payload DM4, a potent tubulin inhibitor, the biologic medicine offers expansion opportunities in e
Keys to Success for Social Media in Healthcare Advertising
PharmExec
DECEMBER 1, 2023
How to build a loyal audience of brand evangelists.
The Importance of Pharmacists in Care Teams for Pregnant People with Diabetes
Drug Topics
DECEMBER 1, 2023
A Q&A with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP, director of education and training in diabetes technology at the Cleveland Clinic.
Don’t Get Distracted By AI, Instead Focus on Intellectual Property
PharmExec
DECEMBER 1, 2023
Artificial intelligence is making it quicker to get drug candidates to the clinic, but it isn’t addressing the fundamental need to marry the right candidate and the right target to the right disease.
J&J, AbbVie, Sanofi and many other companies face competition probe in Turkey
Fierce Pharma
DECEMBER 1, 2023
Turkish authorities have launched an investigation into 19 pharmaceutical companies to probe whether their operations violated the country’s competition law, the Turkish Competition Authority discl | The companies, which include Pfizer, J&J, Sanofi, AbbVie, AstraZeneca, Merck and others are being probed for potentially violating Turkish competition law, according to a release from the country's government.
Cybin preps for ph3 as psychedelic clears depression trial
pharmaphorum
DECEMBER 1, 2023
Cybin preps for ph3 as psychedelic clears depression trial Phil.
FDA Priority Review Granted to Keytruda/Padcev Combo for Locally Advanced, Metastatic Urothelial Carcinoma
Pharmaceutical Commerce
DECEMBER 1, 2023
In clinical trials, Keytruda plus Padcev lowered the risk of disease progression or death by 55% compared with chemotherapy in adult patients with locally advanced or metastatic urothelial carcinoma.
STAT Virtual Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D
STAT
DECEMBER 1, 2023
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET. After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.
Giant's dietitians kick off virtual classes in December to build holiday boards
Drug Store News
DECEMBER 1, 2023
Giant is kicking off free virtual well-being classes featuring festive board ideas throughout December.
STAT+: Up and down the ladder: The latest comings and goings
STAT
DECEMBER 1, 2023
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.
Healthcare Dealmakers—Cigna-Humana merger murmurs; PE's health tech pickups and more
Fierce Healthcare
DECEMBER 1, 2023
Healthcare mergers and acquisitions are in no short supply as providers, health tech companies, retailers and other industry players look to expand their businesses and gain a competitive edge. | A $10 billion Missouri health system merger, Virgin Pulse and HealthComp's $3 billion combination and more merger and acquisition news from the month of November.
STAT+: Pharmalittle: Pfizer halts development of twice-daily obesity pill; Supreme Court to review Purdue bankruptcy deal
STAT
DECEMBER 1, 2023
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to promenade with the official mascots, tidy up the leafy grounds, and maybe have a listening party with Mrs. Pharmalot. The rotation will likely include this , this , this and this.
5 foods to avoid while taking Ozempic
The Checkup by Singlecare
DECEMBER 1, 2023
For people with Type 2 diabetes, Ozempic is a game-changer: This FDA-approved drug not only lowers blood sugar but can also help people lose weight. Lower blood sugar and weight loss can lead to better health and wellness outcomes for people with diabetes, who are at a higher risk for heart disease, stroke, kidney failure, and vision loss. One of the ways Ozempic (semaglutide) and other GLP-1 receptor agonists work is by decreasing appetite.
MSD, Amgen back patient data specialist Culmination Bio
pharmaphorum
DECEMBER 1, 2023
MSD, Amgen back patient data specialist Culmination Bio Phil.
AstraZeneca calls it quits on pair of trials for hyperkalemia drug it scored in buyout of ZS Pharma
Fierce Pharma
DECEMBER 1, 2023
After a hard-fought battle for FDA approval, AstraZeneca has hit another setback on its quest to turn its potassium-reduction drug Lokelma into a blockbuster. | AstraZeneca has put the kibosh on two late-stage Lokelma trials testing the hyperkalemia drug in patients with heart and kidney diseases. The studies were called off due to “substantially increased enrollment times and low event rates,” AZ said Friday.
Let's personalize your content